Valomaciclovir Stearate | MIV-606 | EPB-348 | CAS#195156-77-5 | DNA Polymerase Inhibitor

Valomaciclovir stearate
new

featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 558295

CAS#: 195156-77-5 (stearate)

Description: Valomaciclovir stearate (A-174606.0; ABT-606; EPB-348; MIV-606; RP-606) is a DNA polymerase inhibitor potentially for treatment of acute herpes zoster and EB virus infection. Valomaciclovir stearate is an orally available and a prodrug of Valomaciclovir with broad-spectrum antiviral activity against a variety of important herpesviruses, including Epstein-Barr virus, or EBV (the first virus to be directly associated with human cancer), varicella zoster virus, or herpes zoster (cause of shingles), and herpes simplex virus 1 and 2.

Chemical Structure

Valomaciclovir stearate

CAS# 195156-77-5 (stearate)

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 558295
Name: Valomaciclovir stearate
CAS#: 195156-77-5 (stearate)
Chemical Formula: C33H58N6O5
Exact Mass: 618.45
Molecular Weight: 618.864
Elemental Analysis: C, 64.05; H, 9.45; N, 13.58; O, 12.93

Price and Availability

Size	Price	Availability
1mg	USD 150	Ready to Ship
5mg	USD 550	Ready to Ship
10mg	USD 950	Ready to Ship
25mg	USD 1650	Ready to Ship
50mg	USD 2950	Ready to Ship
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Related CAS #: 195156-77-5 (stearate) 195157-39-2 (HCl) 195156-78-6 (TFA)

Synonym: Valomaciclovir stearate; A-174606.0; A 174606.0; A174606.0; ABT-606; ABT 606; ABT606; EPB-348; EPB348; EPB 348; MIV-606; MIV 606; MIV606; RP-606; RP606; RP 606;

IUPAC/Chemical Name: (R)-4-((L-valyl)oxy)-2-((2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl)butyl stearate

InChi Key: ACBSZTQIFTYFGH-IAPPQJPRSA-N

InChi Code: InChI=1S/C33H58N6O5/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-27(40)44-23-26(20-21-43-32(42)28(34)25(2)3)22-39-24-36-29-30(39)37-33(35)38-31(29)41/h24-26,28H,4-23,34H2,1-3H3,(H3,35,37,38,41)/t26-,28+/m1/s1

SMILES Code: N[C@@H](C(C)C)C(OCC[C@H](CN1C=NC2=C1N=C(N)NC2=O)COC(CCCCCCCCCCCCCCCCC)=O)=O

Appearance: White to off-white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Note: CAS#195157-34-7 (Valomaciclovir)

Product Data:

Product Data

Certificate of Analysis:

View CoA: current batch, Lot#H23P03S01

QC Data:

View QC data: current batch, Lot#H23P03S01

Safety Data Sheet (SDS):

View Safety Data Sheet (SDS)

Instruction:

View handling instruction

Biological target:	Valomaciclovir stearate (A-174606.0; ABT-606; EPB-348; MIV-606; RP-606) is a DNA polymerase inhibitor.
In vitro activity:	TBD
In vivo activity:	TBD

Preparing Stock Solutions

The following data is based on the product molecular weight 618.86 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	TBD
In vitro protocol:	TBD
In vivo protocol:	TBD

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Andrei G, Snoeck R. Advances and Perspectives in the Management of Varicella- Zoster Virus Infections. Molecules. 2021 Feb 20;26(4):1132. doi: 10.3390/molecules26041132. PMID: 33672709; PMCID: PMC7924330.

2: Krecmerova M. Amino Acid Ester Prodrugs of Nucleoside and Nucleotide Antivirals. Mini Rev Med Chem. 2017;17(10):818-833. doi: 10.2174/1389557517666170216151601. PMID: 28215138.

3: El Hayderi L, Rübben A, Nikkels AF. Alpha-Herpesviridae in der Dermatologie : Herpes-simplex-Virus Typ I und II [The alpha-herpesviridae in dermatology : Herpes simplex virus types I and II. German version]. Hautarzt. 2017 Mar;68(3):181-186. German. doi: 10.1007/s00105-016-3929-5. PMID: 28197699.

4: El Hayderi L, Rübben A, Nikkels AF. The alpha-herpesviridae in dermatology : Herpes simplex virus types I and II. Hautarzt. 2017 Dec;68(Suppl 1):1-5. English. doi: 10.1007/s00105-016-3919-7. PMID: 28197698.

5: De Paor M, O'Brien K, Fahey T, Smith SM. Antiviral agents for infectious mononucleosis (glandular fever). Cochrane Database Syst Rev. 2016 Dec 8;12(12):CD011487. doi: 10.1002/14651858.CD011487.pub2. PMID: 27933614; PMCID: PMC6463965.

6: De SK, Hart JC, Breuer J. Herpes simplex virus and varicella zoster virus: recent advances in therapy. Curr Opin Infect Dis. 2015 Dec;28(6):589-95. doi: 10.1097/QCO.0000000000000211. PMID: 26524331.

7: Andrei G, Snoeck R. Advances in the treatment of varicella-zoster virus infections. Adv Pharmacol. 2013;67:107-68. doi: 10.1016/B978-0-12-405880-4.00004-4. PMID: 23886000.

8: Tyring SK, Plunkett S, Scribner AR, Broker RE, Herrod JN, Handke LT, Wise JM, Martin PA; Valomaciclovir Zoster Study Group. Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: a randomized, double-blind, active-controlled trial. J Med Virol. 2012 Aug;84(8):1224-32. doi: 10.1002/jmv.23329. PMID: 22711350.

9: Price NB, Prichard MN. Progress in the development of new therapies for herpesvirus infections. Curr Opin Virol. 2011 Dec;1(6):548-54. doi: 10.1016/j.coviro.2011.10.015. PMID: 22162744; PMCID: PMC3230035.

10: Andrei G, Snoeck R. Emerging drugs for varicella-zoster virus infections. Expert Opin Emerg Drugs. 2011 Sep;16(3):507-35. doi: 10.1517/14728214.2011.591786. Epub 2011 Jun 24. PMID: 21699441.

Your view history

Valomaciclovir stearate new featured